title: Association between HLA-Class I and HLA-Class II Alleles and Mycobacterium Tuberculosis Infection in Iraqi Patients from Baghdad City.
abstract: BACKGROUND
  Pulmonary tuberculosis (PT) is one of the endemic diseases in Iraq, and among the suggested predisposing factors are alleles of the human leukocyte antigen (HLA) system. We sought to investigate the association between HLA-class I (A and B) and -class II (DR and DQ) alleles in a sample of PT Iraqi patients.
  
  
  METHODS
  lymphocytes of 105 PT patients and 40 controls were phenotyped for HLA-A, -B, -DR, and -DQ alleles by means of the microlymphocytotoxicity test using a panel of monoclonal antisera.
  
  
  RESULTS
  HLA frequencies of B18 (16.2 vs. 2.5%; OD=7.53) and DR1 (51.4 vs. 10.0%; OD=9.53) alleles were significantly increased in the patients as compared with the controls, while B5 (6.7 vs. 25.0%), DR8 (1.9 vs. 17.5%), and DQ3 (11.4 vs. 45.0%) alleles were significantly decreased. However, a significant corrected level was maintained for only DR1, DR8, and DQ3 alleles (Pc=1.9×10(-5), 0.02 and 1.0×10(-4), respectively).
  
  
  CONCLUSIONS
  The results confirm the predisposing and protecting roles of HLA alleles in PT.
authors.affiliation: Department of Microbiology, Al-Nahrain College of Medicine, Al-Nahrain University, Baghdad, Iraq;
authors.forename: Nidhal Abdulmohaimen
authors.initials: NA
authors.lastname: Mohammed
authors.affiliation: Microbiologist, College of Pharmacy, Al Mustansiyria University, Baghdad, Iraq;
authors.forename: Haitham
authors.initials: H
authors.lastname: Qassem
authors.affiliation: Department of Microbiology, College of Medicine, Al Mustansiyria University, Baghdad, Iraq.
authors.forename: Farouk
authors.initials: F
authors.lastname: Hassen
keywords: Lymphocytotoxicity; MHC-Class I; MHC-Class II; Tuberculosis
references.citation: Int J Tuberc Lung Dis. 2006 Jul;10(7):717-25
references.pmid: 16848331
references.citation: Clin Vaccine Immunol. 2010 Jan;17(1):168-75
references.pmid: 19864486
references.citation: Hum Immunol. 2006 Aug;67(8):643-54
references.pmid: 16916662
references.citation: JAMA. 1998 Jan 21;279(3):226-8
references.pmid: 9438744
references.citation: Int J Tuberc Lung Dis. 2004 Aug;8(8):1017-21
references.pmid: 15305487
references.citation: Nature. 1964 Dec 5;204:998-1000
references.pmid: 14248725
references.citation: Clin Dev Immunol. 2011;2011:549023
references.pmid: 21876708
references.citation: Immunology. 2010 Apr;129(4):496-505
references.pmid: 20002212
references.citation: Front Immunol. 2012 Mar 05;3:40
references.pmid: 22566923
references.citation: Epidemiol Rev. 1989;11:79-98
references.pmid: 2680563
references.citation: PLoS Pathog. 2009 Apr;5(4):e1000374
references.pmid: 19360129
references.citation: Tuber Lung Dis. 1999;79(4):199-206
references.pmid: 10692987
references.citation: PLoS Pathog. 2007 Sep 21;3(9):1240-9
references.pmid: 17892322
references.citation: Infect Genet Evol. 2006 Nov;6(6):436-9
references.pmid: 16563877
references.citation: Immunol Rev. 2011 Mar;240(1):252-68
references.pmid: 21349098
references.citation: Sarcoidosis Vasc Diffuse Lung Dis. 2008 Sep;25(1):21-8
references.pmid: 19070257
references.citation: Hum Immunol. 2005 Oct;66(10):1074-81
references.pmid: 16386650
references.citation: Braz J Infect Dis. 2008 Aug;12(4):278-80
references.pmid: 19030725
references.citation: J Infect Dis. 2004 Mar 15;189(6):1084-90
references.pmid: 14999612
references.citation: Tuber Lung Dis. 1997;78(3-4):171-4
references.pmid: 9713649
references.citation: Int J Immunogenet. 2009 Jun;36(3):129-33
references.pmid: 19392836